生血宁片治疗维持性血液透析患者贫血的临床观察

【】　目的　比较生血宁片和多糖铁复合物胶囊两种口服铁剂在治疗维持性血液透析患者肾性贫血中的治疗效果。　方法　2008年12月-2010年6月间选择40例维持性血液透析贫血患者，随机分为生血宁片组和多糖铁复合物胶囊组，每组20例，观察期为8周。分别检测两组患者用药前及用药后4、8周时血红蛋白、红细胞压积、血清铁蛋白、转铁蛋白饱和度等指标情况。同时两组患者均使用基因重组人促红细胞生成素，按100~120U/（kg？周），分两次皮下注射。　结果　治疗前两组指标无明显差异，治疗后两组患者的血红蛋白、红细胞压积、血清铁蛋白以及转铁蛋白饱和度较治疗前均显著上升，且两组患者升高的幅度相比，生血宁组升高的幅度更显著。治疗结束时，两组患者不良反应方面的差异无统计学意义。　结论　两种口服铁剂均能有效地纠正血液透析患者的铁缺乏及贫血状况；生血宁片组的作用更显著，且还具备降低患者促红细胞生成素使用量的作用。【Abstract】　Objective　TocomparetheeffectofShengxueningpieceandcapsulepolysaccharide-ironcomplexonanemiainhemodialysispatients.　Methods　Atotalof40patientswithanemiainmaintenancehemodialysistreatedbetweenDecember2008andJune2010wererandomlydividedintoShengxueningpiecegroupandcapsulepolysaccharide-ironcomplexgroup;thepatientswereobservedfor8weeks.Hemoglobin(Hb),hematocrit(Hct),serumferritin(SF),transferrinsaturation(TSAT)andotherindicatorsweredetectedbeforetreatmentfourandeightweeksafterthetreatment.Whilepatientswereusedrecombinanthumanerythropoietin(EPO)accordingto100-120U/(kg？week),twicesubcutaneousinjection.　Results　Beforetreatment,therewasnosignificantdifferencebetweenthetwogroups.Hb,Hct,SFandTSATincreasedsignificantlyaftertreatmentinbothofthegroupsandspeciallyintheShengxueningpiecegroup.Afterthetreatment,thedifferenceintheadversereactionbetweenthetwogroupswasnotsignificant.　Conclusions　Bothoralironcaneffectivelycorrectthehemodialysispatientswithirondeficiencyandanemia.However,Shengxueninghasmoresignificantroleandmayreducetheuseoferythropoietininpatientswithhemodialysis.